AU2017339581A1 - Immunosuppression-reverting oligonucleotides inhibiting the expression of CD73 - Google Patents

Immunosuppression-reverting oligonucleotides inhibiting the expression of CD73 Download PDF

Info

Publication number: AU2017339581A1
Authority: AU; Australia
Prior art keywords: seq; oligonucleotide; cells; cancer; pharmaceutical composition
Prior art date: 2016-10-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2017339581A

Other languages

English (en)

Inventor

Tamara HILMENYUK

Frank Jaschinski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Secarna Pharmaceuticals GmbH and Co KG

Original Assignee

Secarna Pharmaceuticals GmbH and Co KG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-07

Filing date

2017-10-09

Publication date

2019-05-02

2017-10-09 Application filed by Secarna Pharmaceuticals GmbH and Co KG filed Critical Secarna Pharmaceuticals GmbH and Co KG

2019-05-02 Publication of AU2017339581A1 publication Critical patent/AU2017339581A1/en

Status Abandoned legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 141
101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 title claims abstract description 85
102100022464 5'-nucleotidase Human genes 0.000 title claims abstract description 83
206010062016 Immunosuppression Diseases 0.000 title claims abstract description 16
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract description 21
230000002401 inhibitory effect Effects 0.000 title description 7
125000003729 nucleotide group Chemical group 0.000 claims abstract description 28
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
239000002773 nucleotide Substances 0.000 claims abstract description 16
150000007523 nucleic acids Chemical group 0.000 claims abstract description 8
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 198
206010028980 Neoplasm Diseases 0.000 claims description 40
201000011510 cancer Diseases 0.000 claims description 18
150000003384 small molecules Chemical class 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
238000000034 method Methods 0.000 claims description 10
210000001519 tissue Anatomy 0.000 claims description 10
230000001684 chronic effect Effects 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 8
230000006028 immune-suppresssive effect Effects 0.000 claims description 8
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 7
208000026310 Breast neoplasm Diseases 0.000 claims description 7
102000002698 KIR Receptors Human genes 0.000 claims description 7
108010043610 KIR Receptors Proteins 0.000 claims description 7
-1 CD 160 Proteins 0.000 claims description 6
102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 6
101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 6
230000004936 stimulating effect Effects 0.000 claims description 6
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
230000000973 chemotherapeutic effect Effects 0.000 claims description 5
102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
208000003174 Brain Neoplasms Diseases 0.000 claims description 4
102100027207 CD27 antigen Human genes 0.000 claims description 4
108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 4
101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 4
101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 4
101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 4
102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 4
108020003285 Isocitrate lyase Proteins 0.000 claims description 4
101150069255 KLRC1 gene Proteins 0.000 claims description 4
102000017578 LAG3 Human genes 0.000 claims description 4
101150030213 Lag3 gene Proteins 0.000 claims description 4
102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 4
101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 4
102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 4
101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 4
102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 4
101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 4
229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims description 4
102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 4
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
229960005277 gemcitabine Drugs 0.000 claims description 4
208000005017 glioblastoma Diseases 0.000 claims description 4
208000026278 immune system disease Diseases 0.000 claims description 4
208000020816 lung neoplasm Diseases 0.000 claims description 4
230000003211 malignant effect Effects 0.000 claims description 4
239000010445 mica Substances 0.000 claims description 4
229910052618 mica group Inorganic materials 0.000 claims description 4
108020004707 nucleic acids Proteins 0.000 claims description 4
102000039446 nucleic acids Human genes 0.000 claims description 4
201000008968 osteosarcoma Diseases 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
229910052697 platinum Inorganic materials 0.000 claims description 4
201000000849 skin cancer Diseases 0.000 claims description 4
206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 3
108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims description 3
102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims description 3
208000020016 psychiatric disease Diseases 0.000 claims description 3
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
208000003200 Adenoma Diseases 0.000 claims description 2
206010001233 Adenoma benign Diseases 0.000 claims description 2
206010003571 Astrocytoma Diseases 0.000 claims description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
206010005949 Bone cancer Diseases 0.000 claims description 2
208000018084 Bone neoplasm Diseases 0.000 claims description 2
206010008263 Cervical dysplasia Diseases 0.000 claims description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
208000007569 Giant Cell Tumors Diseases 0.000 claims description 2
208000037147 Hypercalcaemia Diseases 0.000 claims description 2
208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 claims description 2
208000009164 Islet Cell Adenoma Diseases 0.000 claims description 2
208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
208000007054 Medullary Carcinoma Diseases 0.000 claims description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
206010060862 Prostate cancer Diseases 0.000 claims description 2
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
201000000582 Retinoblastoma Diseases 0.000 claims description 2
206010039491 Sarcoma Diseases 0.000 claims description 2
201000010208 Seminoma Diseases 0.000 claims description 2
208000000453 Skin Neoplasms Diseases 0.000 claims description 2
208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
208000008383 Wilms tumor Diseases 0.000 claims description 2
208000009956 adenocarcinoma Diseases 0.000 claims description 2
230000001919 adrenal effect Effects 0.000 claims description 2
206010002224 anaplastic astrocytoma Diseases 0.000 claims description 2
210000000621 bronchi Anatomy 0.000 claims description 2
208000002458 carcinoid tumor Diseases 0.000 claims description 2
210000001072 colon Anatomy 0.000 claims description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
210000000232 gallbladder Anatomy 0.000 claims description 2
201000008361 ganglioneuroma Diseases 0.000 claims description 2
210000003128 head Anatomy 0.000 claims description 2
230000000148 hypercalcaemia Effects 0.000 claims description 2
208000030915 hypercalcemia disease Diseases 0.000 claims description 2
206010020718 hyperplasia Diseases 0.000 claims description 2
230000000968 intestinal effect Effects 0.000 claims description 2
201000002529 islet cell tumor Diseases 0.000 claims description 2
210000003734 kidney Anatomy 0.000 claims description 2
206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
206010024627 liposarcoma Diseases 0.000 claims description 2
201000007270 liver cancer Diseases 0.000 claims description 2
208000014018 liver neoplasm Diseases 0.000 claims description 2
201000005202 lung cancer Diseases 0.000 claims description 2
208000037841 lung tumor Diseases 0.000 claims description 2
230000000527 lymphocytic effect Effects 0.000 claims description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
201000001441 melanoma Diseases 0.000 claims description 2
206010027191 meningioma Diseases 0.000 claims description 2
230000001394 metastastic effect Effects 0.000 claims description 2
206010061289 metastatic neoplasm Diseases 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
210000003739 neck Anatomy 0.000 claims description 2
230000001537 neural effect Effects 0.000 claims description 2
210000000496 pancreas Anatomy 0.000 claims description 2
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 2
230000000849 parathyroid Effects 0.000 claims description 2
208000030266 primary brain neoplasm Diseases 0.000 claims description 2
210000000664 rectum Anatomy 0.000 claims description 2
208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
201000008261 skin carcinoma Diseases 0.000 claims description 2
206010040882 skin lesion Diseases 0.000 claims description 2
231100000444 skin lesion Toxicity 0.000 claims description 2
208000000649 small cell carcinoma Diseases 0.000 claims description 2
210000002784 stomach Anatomy 0.000 claims description 2
230000002381 testicular Effects 0.000 claims description 2
210000001685 thyroid gland Anatomy 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
238000012230 antisense oligonucleotides Methods 0.000 description 91
239000000074 antisense oligonucleotide Substances 0.000 description 88
108020004999 messenger RNA Proteins 0.000 description 71
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 56
108020000948 Antisense Oligonucleotides Proteins 0.000 description 43
230000000694 effects Effects 0.000 description 37
239000002126 C01EB10 - Adenosine Substances 0.000 description 28
229960005305 adenosine Drugs 0.000 description 28
241000699666 Mus <mouse, genus> Species 0.000 description 16
210000001744 T-lymphocyte Anatomy 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
238000012216 screening Methods 0.000 description 13
239000006228 supernatant Substances 0.000 description 13
230000001506 immunosuppresive effect Effects 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
239000003981 vehicle Substances 0.000 description 12
230000035755 proliferation Effects 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
230000001419 dependent effect Effects 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
108091030071 RNAI Proteins 0.000 description 8
230000009368 gene silencing by RNA Effects 0.000 description 8
229910019142 PO4 Inorganic materials 0.000 description 7
230000003833 cell viability Effects 0.000 description 7
238000000684 flow cytometry Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
239000010452 phosphate Substances 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 6
101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 6
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 6
241001529936 Murinae Species 0.000 description 6
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 6
235000011180 diphosphates Nutrition 0.000 description 6
239000002609 medium Substances 0.000 description 6
108700039887 Essential Genes Proteins 0.000 description 5
102000037982 Immune checkpoint proteins Human genes 0.000 description 5
108091008036 Immune checkpoint proteins Proteins 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
210000002865 immune cell Anatomy 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
208000036832 Adenocarcinoma of ovary Diseases 0.000 description 4
208000022559 Inflammatory bowel disease Diseases 0.000 description 4
101100026203 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) neg-1 gene Proteins 0.000 description 4
206010061328 Ovarian epithelial cancer Diseases 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
208000013371 ovarian adenocarcinoma Diseases 0.000 description 4
201000007426 ovarian cystadenocarcinoma Diseases 0.000 description 4
201000006588 ovary adenocarcinoma Diseases 0.000 description 4
238000001890 transfection Methods 0.000 description 4
108050000203 Adenosine receptors Proteins 0.000 description 3
102000009346 Adenosine receptors Human genes 0.000 description 3
102000008203 CTLA-4 Antigen Human genes 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
239000006143 cell culture medium Chemical group 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010219 correlation analysis Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
238000011835 investigation Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
239000000047 product Substances 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000012096 transfection reagent Substances 0.000 description 3
YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
108700012813 7-aminoactinomycin D Proteins 0.000 description 2
101150051188 Adora2a gene Proteins 0.000 description 2
206010071155 Autoimmune arthritis Diseases 0.000 description 2
102000008096 B7-H1 Antigen Human genes 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
102100024263 CD160 antigen Human genes 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
101150017921 DDIT3 gene Proteins 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000186366 Mycobacterium bovis Species 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
OLCWZBFDIYXLAA-IOSLPCCCSA-N adenosine 5'-methylenediphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O OLCWZBFDIYXLAA-IOSLPCCCSA-N 0.000 description 2
208000037883 airway inflammation Diseases 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
206010009887 colitis Diseases 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000001177 diphosphate Substances 0.000 description 2
MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
102000045309 human NT5E Human genes 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
101710125610 Adenosine receptor A2a Proteins 0.000 description 1
102100035990 Adenosine receptor A2a Human genes 0.000 description 1
102100036006 Adenosine receptor A3 Human genes 0.000 description 1
101710128949 Adenosine receptor A3 Proteins 0.000 description 1
101150078577 Adora2b gene Proteins 0.000 description 1
241001270131 Agaricus moelleri Species 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
238000011529 RT qPCR Methods 0.000 description 1
101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000008106 antitumoral immune reaction Effects 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000050 cytotoxic potential Toxicity 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
108010047482 ectoATPase Proteins 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000002530 ischemic preconditioning effect Effects 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
210000000581 natural killer T-cell Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03005—5'-Nucleotidase (3.1.3.5)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Virology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU2017339581A 2016-10-07 2017-10-09 Immunosuppression-reverting oligonucleotides inhibiting the expression of CD73 Abandoned AU2017339581A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP16192798.3		2016-10-07
EP16192798		2016-10-07
EP17187805.1		2017-08-24
EP17187805		2017-08-24
PCT/EP2017/075682 WO2018065627A1 (fr)	2016-10-07	2017-10-09	Oligonucléotides d'inversion de l'immunosuppression inhibant l'expression de cd73

Publications (1)

Publication Number	Publication Date
AU2017339581A1 true AU2017339581A1 (en)	2019-05-02

Family

ID=60153282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2017339581A Abandoned AU2017339581A1 (en)	2016-10-07	2017-10-09	Immunosuppression-reverting oligonucleotides inhibiting the expression of CD73

Country Status (7)

Country	Link
EP (1)	EP3523436A1 (fr)
JP (1)	JP2019531095A (fr)
KR (1)	KR20190077390A (fr)
CN (1)	CN110168088A (fr)
AU (1)	AU2017339581A1 (fr)
CA (1)	CA3039077A1 (fr)
WO (1)	WO2018065627A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR102018001541B1 (pt) *	2018-01-24	2021-05-11	Universidade Federal Do Rio Grande Do Sul	composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência
IL284745B2 (en)	2019-01-11	2025-08-01	Omeros Corp	Compositions comprising gpr174 inhibitory compounds and uses thereof for treating cancer
KR20220070275A (ko) *	2019-10-04	2022-05-30	세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지	올리고뉴클레오티드 기반 생체외 세포 요법
CN115176010A (zh) *	2020-02-28	2022-10-11	豪夫迈·罗氏有限公司	用于调节cd73外显子7剪接的寡核苷酸
JP2023528071A (ja) *	2020-06-03	2023-07-03	エムヴィバイオセラピューティクスエスエー	Ａｔｐ加水分解酵素と免疫チェックポイントモジュレーターとの組合せ、並びにその使用
CN116997652A (zh)	2020-12-31	2023-11-03	瑟卡尔纳制药有限公司	减少cd73 mrna的量和cd73蛋白表达的寡核苷酸
CN119173276A (zh)	2022-04-13	2024-12-20	吉利德科学公司	用于治疗表达Trop-2的癌症的组合疗法
US20250230168A1 (en)	2023-12-22	2025-07-17	Gilead Sciences, Inc.	Azaspiro wrn inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004079013A1 (fr) *	2003-03-03	2004-09-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Ecto-5’-nucleotidase (cd73) utilisee dans le diagnostic et le traitement du cancer du pancreas
EP1752536A4 (fr) *	2004-05-11	2008-04-16	Alphagen Co Ltd	Polynucleotide provoquant l'interference rna et procede de regulation d'expression genetique avec l'usage de ce dernier
WO2012012736A2 (fr) *	2010-07-23	2012-01-26	The Ohio State University	Procédé de traitement d'un dysfonctionnement dû à une infection virale par perturbation de la voie du récepteur de l'adénosine
BR112015024729B1 (pt)	2013-03-27	2022-02-15	Isarna Therapeutics Gmbh	Oligonucleotídeo antissenso, seu uso e composição farmacêutica
US20160129108A1 (en) *	2014-11-11	2016-05-12	Medimmune Limited	Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
EP3259288A1 (fr) *	2015-02-20	2017-12-27	Innate Pharma	Blocage de cd73
WO2016138278A2 (fr) *	2015-02-27	2016-09-01	Idera Pharmaceuticals, Inc.	Compositions permettant d'inhiber l'expression de gène checkpoint et leurs utilisations

2017
- 2017-10-09 KR KR1020197013136A patent/KR20190077390A/ko not_active Withdrawn
- 2017-10-09 CN CN201780073579.6A patent/CN110168088A/zh active Pending
- 2017-10-09 JP JP2019540697A patent/JP2019531095A/ja active Pending
- 2017-10-09 CA CA3039077A patent/CA3039077A1/fr not_active Abandoned
- 2017-10-09 WO PCT/EP2017/075682 patent/WO2018065627A1/fr not_active Ceased
- 2017-10-09 EP EP17787366.8A patent/EP3523436A1/fr not_active Withdrawn
- 2017-10-09 AU AU2017339581A patent/AU2017339581A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN110168088A (zh)	2019-08-23
JP2019531095A (ja)	2019-10-31
KR20190077390A (ko)	2019-07-03
CA3039077A1 (fr)	2018-04-12
WO2018065627A1 (fr)	2018-04-12
EP3523436A1 (fr)	2019-08-14

Publication	Publication Date	Title
AU2017339581A1 (en)	2019-05-02	Immunosuppression-reverting oligonucleotides inhibiting the expression of CD73
US11959083B2 (en)	2024-04-16	Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
US20230183708A1 (en)	2023-06-15	PD-1-specific antisense oligonucleotide and its use in therapy
US11781136B2 (en)	2023-10-10	Oligonucleotide inhibiting the expression of Chop
WO2020011909A1 (fr)	2020-01-16	Polymères d'acides nucléiques inhibant l'expression de xbp1
US20240076673A1 (en)	2024-03-07	Oligonucleotides reducing the amount of CD73 mRNA and CD73 protein expression
US20200163988A1 (en)	2020-05-28	Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of IDO
US20230067620A1 (en)	2023-03-02	Inhibitor of metadherin expression
CA3217457A1 (fr)	2022-11-10	Compositions d'immunotherapie d'arn a ciblage multiple
IL294311A (en)	2022-08-01	Modified antisense oligonucleotides for monitoring the expression of foxp3
NZ793165A (en)	2022-10-28	Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
HK40049835A (en)	2021-12-24	Inhibitor of metadherin expression
EP3346007A1 (fr)	2018-07-11	Oligonucléotides à immunosuppression inversée inhibant l'expression de la tdo

Legal Events

Date	Code	Title	Description
2021-10-07	MK1	Application lapsed section 142(2)(a) - no request for examination in relevant period